168 related articles for article (PubMed ID: 10068658)
1. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma.
Vescio R; Schiller G; Stewart AK; Ballester O; Noga S; Rugo H; Freytes C; Stadtmauer E; Tarantolo S; Sahebi F; Stiff P; Meharchard J; Schlossman R; Brown R; Tully H; Benyunes M; Jacobs C; Berenson R; DiPersio J; Anderson K; Berenson J
Blood; 1999 Mar; 93(6):1858-68. PubMed ID: 10068658
[TBL] [Abstract][Full Text] [Related]
2. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial.
Stewart AK; Vescio R; Schiller G; Ballester O; Noga S; Rugo H; Freytes C; Stadtmauer E; Tarantolo S; Sahebi F; Stiff P; Meharchard J; Schlossman R; Brown R; Tully H; Benyunes M; Jacobs C; Berenson R; White M; DiPersio J; Anderson KC; Berenson J
J Clin Oncol; 2001 Sep; 19(17):3771-9. PubMed ID: 11533101
[TBL] [Abstract][Full Text] [Related]
3. Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution.
Michallet M; Philip T; Philip I; Godinot H; Sebban C; Salles G; Thiebaut A; Biron P; Lopez F; Mazars P; Roubi N; Leemhuis T; Hanania E; Reading C; Fine G; Atkinson K; Juttner C; Coiffier B; Fière D; Archimbaud E
Exp Hematol; 2000 Jul; 28(7):858-70. PubMed ID: 10907648
[TBL] [Abstract][Full Text] [Related]
4. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma.
Schiller G; Vescio R; Freytes C; Spitzer G; Sahebi F; Lee M; Wu CH; Cao J; Lee JC; Hong CH
Blood; 1995 Jul; 86(1):390-7. PubMed ID: 7540888
[TBL] [Abstract][Full Text] [Related]
5. A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis.
Gandhi M; Jestice H; Scott M; Bloxham D; Bass G; Craig J; Marcus R
Bone Marrow Transplant; 1999 Aug; 24(4):369-75. PubMed ID: 10467325
[TBL] [Abstract][Full Text] [Related]
6. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells.
Lemoli RM; Fortuna A; Motta MR; Rizzi S; Giudice V; Nannetti A; Martinelli G; Cavo M; Amabile M; Mangianti S; Fogli M; Conte R; Tura S
Blood; 1996 Feb; 87(4):1625-34. PubMed ID: 8608257
[TBL] [Abstract][Full Text] [Related]
7. Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study.
Bourhis JH; Bouko Y; Koscielny S; Bakkus M; Greinix H; Derigs G; Salles G; Feremans W; Apperley J; Samson D; Björkstrand B; Niederwieser D; Gahrton G; Pico JL; Goldschmidt H;
Haematologica; 2007 Aug; 92(8):1083-90. PubMed ID: 17640853
[TBL] [Abstract][Full Text] [Related]
8. High-dose CD34+ cells are not clinically relevant in reducing cytopenia and blood component consumption following myeloablative therapy and peripheral blood progenitor cell transplantation as compared with standard dose.
Lefrère F; Delarue R; Somme D; Levy V; Damaj G; Tu A; Porcher R; Audat F; Boulat C; Cavazzana-Calvo M; Buzyn A; Belanger C; Maillard N; Hermine O; Varet B
Transfusion; 2002 Apr; 42(4):443-50. PubMed ID: 12076291
[TBL] [Abstract][Full Text] [Related]
9. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
10. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
Klaus J; Herrmann D; Breitkreutz I; Hegenbart U; Mazitschek U; Egerer G; Cremer FW; Lowenthal RM; Huesing J; Fruehauf S; Moehler T; Ho AD; Goldschmidt H
Eur J Haematol; 2007 Jan; 78(1):21-8. PubMed ID: 17042762
[TBL] [Abstract][Full Text] [Related]
11. Autologous CD34+ cell transplantation for patients with advanced lymphoma: effects of overnight storage on peripheral blood progenitor cell enrichment and engraftment.
Koç ON; Gerson SL; Phillips GL; Cooper BW; Kutteh L; Van Zant G; Reece DE; Fox RM; Schupp JE; Tainer N; Lazarus HM
Bone Marrow Transplant; 1998 Feb; 21(4):337-43. PubMed ID: 9509966
[TBL] [Abstract][Full Text] [Related]
12. Selection and transplantation of autologous hematopoietic CD34+ cells for patients with multiple myeloma.
Lemoli RM; Fortuna A; Raspadori D; Ventura MA; Martinelli G; Gozzetti A; Leopardi G; Ratta M; Cavo M; Tura S
Leuk Lymphoma; 1997 Dec; 26 Suppl 1():1-11. PubMed ID: 9570675
[TBL] [Abstract][Full Text] [Related]
13. Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma.
Tricot G; Gazitt Y; Leemhuis T; Jagannath S; Desikan KR; Siegel D; Fassas A; Tindle S; Nelson J; Juttner C; Tsukamoto A; Hallagan J; Atkinson K; Reading C; Hoffman R; Barlogie B
Blood; 1998 Jun; 91(12):4489-95. PubMed ID: 9616143
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: different levels of tumor cell reduction. Implications for autografting.
Lopez M; Lemoine FM; Firat H; Fouillard L; Laporte JP; Lesage S; Isnard F; Stachowiak J; Ferrer-Le Coeur F; Morel P; Najman A; Douay L; Gorin NC
Blood; 1997 Oct; 90(7):2830-8. PubMed ID: 9326252
[TBL] [Abstract][Full Text] [Related]
15. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome.
Patriarca F; Damiani D; Fanin R; Grimaz S; Geromin A; Cerno M; Sperotto A; Silvestri F; Zaja F; Baccarani M
Haematologica; 2000 Mar; 85(3):269-74. PubMed ID: 10702815
[TBL] [Abstract][Full Text] [Related]
16. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma.
Negrin RS; Kusnierz-Glaz CR; Still BJ; Schriber JR; Chao NJ; Long GD; Hoyle C; Hu WW; Horning SJ; Brown BW
Blood; 1995 Jun; 85(11):3334-41. PubMed ID: 7538824
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood stem cell transplantation in myeloma using CD34 selected cells.
Johnson RJ; Owen RG; Smith GM; Child JA; Galvin M; Newton LJ; Rawstron A; Major K; Woodhead V; Robinson F; Jack A; Morgan GJ
Bone Marrow Transplant; 1996 May; 17(5):723-7. PubMed ID: 8733688
[TBL] [Abstract][Full Text] [Related]
18. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
[TBL] [Abstract][Full Text] [Related]
19. Mobilized CD34+ cells selected as autografts in patients with primary light-chain amyloidosis: rationale and application.
Comenzo RL; Michelle D; LeBlanc M; Wally J; Zhang Y; Kica G; Karandish S; Arkin CF; Wright DG; Skinner M; McMannis J
Transfusion; 1998 Jan; 38(1):60-9. PubMed ID: 9482396
[TBL] [Abstract][Full Text] [Related]
20. The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systems.
Roots-Weiss A; Papadimitriou C; Serve H; Hoppe B; Koenigsmann M; Reufi B; Oberberg D; Thiel E; Berdel WE
Bone Marrow Transplant; 1997 Jun; 19(12):1239-46. PubMed ID: 9208119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
